We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agilent (A) Reports Q4 Earnings: What Key Metrics Have to Say
Read MoreHide Full Article
Agilent Technologies (A - Free Report) reported $1.7 billion in revenue for the quarter ended October 2024, representing a year-over-year increase of 0.8%. EPS of $1.46 for the same period compares to $1.38 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $1.67 billion, representing a surprise of +1.65%. The company delivered an EPS surprise of +3.55%, with the consensus EPS estimate being $1.41.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Agilent performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue by End Markets- Pharmaceutical: $595 million compared to the $583.30 million average estimate based on two analysts. The reported number represents a change of +0.9% year over year.
Revenue by End Markets- Academia and Government: $150 million versus the two-analyst average estimate of $138.29 million. The reported number represents a year-over-year change of 0%.
Revenue by End Markets- Diagnostics and Clinical: $255 million compared to the $243.48 million average estimate based on two analysts. The reported number represents a change of +8.1% year over year.
Revenue by End Markets- Chemical and advanced materials: $385 million compared to the $385.60 million average estimate based on two analysts. The reported number represents a change of +1.1% year over year.
Net Revenue- Agilent Crosslab Group: $426 million versus $431.46 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.5% change.
Revenue by End Markets- Environmental and Forensics: $164 million versus the two-analyst average estimate of $167.03 million. The reported number represents a year-over-year change of -6.3%.
Net Revenue- Life Sciences and Applied Markets Group: $833 million versus the two-analyst average estimate of $819.25 million. The reported number represents a year-over-year change of -10.2%.
Net Revenue- Diagnostics and Genomics Group: $442 million compared to the $417.75 million average estimate based on two analysts. The reported number represents a change of +24.2% year over year.
Revenue by End Markets- Food: $152 million versus $158.98 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -2.6% change.
Shares of Agilent have returned +2.8% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Agilent (A) Reports Q4 Earnings: What Key Metrics Have to Say
Agilent Technologies (A - Free Report) reported $1.7 billion in revenue for the quarter ended October 2024, representing a year-over-year increase of 0.8%. EPS of $1.46 for the same period compares to $1.38 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $1.67 billion, representing a surprise of +1.65%. The company delivered an EPS surprise of +3.55%, with the consensus EPS estimate being $1.41.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Agilent performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue by End Markets- Pharmaceutical: $595 million compared to the $583.30 million average estimate based on two analysts. The reported number represents a change of +0.9% year over year.
- Revenue by End Markets- Academia and Government: $150 million versus the two-analyst average estimate of $138.29 million. The reported number represents a year-over-year change of 0%.
- Revenue by End Markets- Diagnostics and Clinical: $255 million compared to the $243.48 million average estimate based on two analysts. The reported number represents a change of +8.1% year over year.
- Revenue by End Markets- Chemical and advanced materials: $385 million compared to the $385.60 million average estimate based on two analysts. The reported number represents a change of +1.1% year over year.
- Net Revenue- Agilent Crosslab Group: $426 million versus $431.46 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.5% change.
- Revenue by End Markets- Environmental and Forensics: $164 million versus the two-analyst average estimate of $167.03 million. The reported number represents a year-over-year change of -6.3%.
- Net Revenue- Life Sciences and Applied Markets Group: $833 million versus the two-analyst average estimate of $819.25 million. The reported number represents a year-over-year change of -10.2%.
- Net Revenue- Diagnostics and Genomics Group: $442 million compared to the $417.75 million average estimate based on two analysts. The reported number represents a change of +24.2% year over year.
- Revenue by End Markets- Food: $152 million versus $158.98 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -2.6% change.
View all Key Company Metrics for Agilent here>>>Shares of Agilent have returned +2.8% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.